Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 14;15(20):4990.
doi: 10.3390/cancers15204990.

Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study

Affiliations

Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study

Rik van den Elshout et al. Cancers (Basel). .

Abstract

Distinguishing treatment-related abnormalities (TRA) from tumor progression (TP) in glioblastoma patients is a diagnostic imaging challenge due to the identical morphology of conventional MR imaging sequences. Diffusion-weighted imaging (DWI) and its derived images of the apparent diffusion coefficient (ADC) have been suggested as diagnostic tools for this problem. The aim of this study is to determine the diagnostic accuracy of different cut-off values of the ADC to differentiate between TP and TRA. In total, 76 post-treatment glioblastoma patients with new contrast-enhancing lesions were selected. Lesions were segmented using a T1-weighted, contrast-enhanced scan. The mean ADC values of the segmentations were compared between TRA and TP groups. Diagnostic accuracy was compared by use of the area under the curve (AUC) and the derived sensitivity and specificity values from cutoff points. Although ADC values in TP (mean = 1.32 × 10-3 mm2/s; SD = 0.31 × 10-3 mm2/s) were significantly different compared to TRA (mean = 1.53 × 10-3 mm2/s; SD = 0.28 × 10-3 mm2/s) (p = 0.003), considerable overlap in their distributions exists. The AUC of ADC values to distinguish TP from TRA was 0.71, with a sensitivity and specificity of 65% and 70%, respectively, at an ADC value of 1.47 × 10-3 mm2/s. These findings therefore indicate that ADC maps should not be used in discerning between TP and TRA at a certain timepoint without information on temporal evolution.

Keywords: apparent diffusion coefficient; diffusion imaging; glioblastoma; receiver operating characteristic curve; treatment-related abnormality; tumor progression.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Axial T1-CE sequences and ADC maps of confirmed TP and TRA patients. (A) Contrast-enhanced T1-weighted images with segmenation; (B) ADC map with segmentation overlay The mean ADC values of the lesions in this figure are TP = 1.14 × 10–3 mm2/s, TRA = 1.68 × 10–3 mm2/s.
Figure 2
Figure 2
ROC analysis based on the ADC values found and literature cut-off. An AUC of 0.71 (95% confidence interval: 0.58–0.83) was yielded with regard to distinguishing TP and TRA on ADC values only. The AUC for combined MGMT status and mean ADC led to an AUC of 0.78 (95% CI: 0.66–0.90). The literature-derived cut-off ADC value of 1.33 × 10–3 mm2/s (13) yielded an AUROC of 0.635 (95% confidence interval: 0.505–0.764).

References

    1. Strauss S.B., Meng A., Ebani E.J., Chiang G.C. Imaging Glioblastoma Posttreatment Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. Neuroimag. Clin. N. Am. 2021;31:103–120. doi: 10.1016/j.nic.2020.09.010. - DOI - PubMed
    1. Vellayappan B., Tan C.L., Yong C., Khor L.K., Koh W.Y., Yeo T.T., Detsky J., Lo S., Sahgal A. Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases. Front. Oncol. 2018;8:395. doi: 10.3389/fonc.2018.00395. - DOI - PMC - PubMed
    1. Merkel A., Soeldner D., Wendl C., Urkan D., Kuramatsu J.B., Seliger C., Proescholdt M., Eyupoglu I.Y., Hau P., Uhl M. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials. J. Neuro Oncol. 2017;132:249–254. doi: 10.1007/s11060-016-2362-z. - DOI - PMC - PubMed
    1. Hagiwara A., Schlossman J., Shabani S., Raymond C., Tatekawa H., Abrey L.E., Garcia J., Chinot O., Saran F., Nishikawa R., et al. Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation. J. Neuro Oncol. 2022;159:509–518. doi: 10.1007/s11060-022-04088-3. - DOI - PubMed
    1. Zhang J., Stevens M.F., Bradshaw T.D. Temozolomide: Mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 2012;5:102–114. doi: 10.2174/1874467211205010102. - DOI - PubMed

LinkOut - more resources